Idarubicin Hikma (Idarubicin Hydrochloride)

Idarubicin intercalates into DNA and blocks topoisomerase II, preventing the resealing of DNA strands during replication. This disruption creates free radicals that cause additional DNA breaks, leading to apoptosis of rapidly dividing cancer cells, especially those of leukemic origin.

The dose of Idarubicin Hikma is individualized by the treating oncologist based on factors such as disease type, patient weight, renal and hepatic function, and prior therapy. Clinicians follow established protocols and adjust dosing according to response and tolerance, without a fixed public regimen.

Idarubicin is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided during pregnancy and women of child‑bearing potential are advised to use effective contraception. Breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant.

To order Idarubicin Hikma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and assists with import documentation.

Idarubicin is structurally related to doxorubicin but is more lipophilic, allowing better cellular uptake and potentially higher potency against leukemic cells. Compared with doxorubicin, idarubicin may have a slightly lower incidence of certain cardiac effects, yet both share similar myelosuppressive and gastrointestinal toxicity profiles. Choice of agent depends on clinical judgment and patient-specific factors.

Idarubicin Hikma should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. If a short‑term storage at controlled room temperature is unavoidable, limit exposure to no more than 24 hours and maintain protection from light.

Idarubicin is given as an intravenous infusion. The drug is typically diluted in a compatible IV fluid and administered over a period ranging from 15 to 30 minutes, depending on the protocol. Administration must be performed by qualified healthcare professionals in a setting equipped for monitoring infusion reactions and cardiac function.

The most critical risks include cardiotoxicity, which can manifest as reduced left‑ventricular function or heart failure, and severe myelosuppression leading to neutropenia, febrile episodes, and bleeding. Additional serious concerns are hepatic toxicity, secondary malignancies, and rare but severe infusion‑related hypersensitivity reactions. Continuous monitoring is essential to detect these complications early.

Idarubicin should be avoided in patients with known hypersensitivity to idarubicin or any anthracycline component, those with severe pre‑existing cardiac dysfunction (e.g., ejection fraction < 50 %), uncontrolled infections, and pregnant or breastfeeding women. Caution is also advised for individuals with significant hepatic impairment or concurrent use of other cardiotoxic agents.